Nucleic acids are an increasingly popular platform for the development of biotherapeutics to treat a wide variety of illnesses, including diseases where traditional drug development efforts have failed. To date, there are 14 short oligonucleotide therapeutics and 2 messenger RNA (mRNA) vaccines approved by the U.S. Food and Drug Administration (FDA), which demonstrates the potential of nucleic acids as a platform for the development of safe and effective medicines and vaccines. Despite the increasing popularity of nucleic acid-based drugs, there has been a paucity of high-resolution structural techniques applied to rigorously characterize these molecules during drug development. Here, we present application of nuclear magnetic resonance (NMR) methods to structurally “fingerprint” short oligonucleotide therapeutics at natural isotope abundance under full formulation conditions. The NMR methods described herein leverage signals arising from the native structural features of nucleic acids, including imino, aromatic, and ribose resonances, in addition to non-native chemistries, such as 2′-fluoro (2′-F), 2′-O-methyl (2′-OMe), and phosphorothioate (PS) modifications, introduced during drug development. We demonstrate the utility of the NMR methods to structurally “fingerprint” a model short interfering RNA (siRNA) and a sample that simulated the drug product Givosiran. We anticipate broad applicability of the NMR methods to other nucleic acid-based therapeutics due to the generalized nature of the approach and ability to monitor many quality attributes simultaneously.
Get full access to this article
View all access options for this article.
References
1.
LiebermanJ. (2018). Tapping the RNA world for therapeutics. Nat Struct Mol Biol, 25:357–364.
2.
CoutinhoMF, MatosL, SantosJI and AlvesS. (2019). RNA therapeutics: how far have we gone? In: The mRNA Metabolism in Human Disease, Advances in Experimental Medicine and Biology 1157. Romao L, ed. Springer Nature, Switzerland AG, Cham, pp. 133–177.
3.
RobertsTC, LangerR and WoodMJA. (2020). Advances in oligonucleotide drug delivery. Nat Rev Drug Discov, 19:673–694.
4.
XiongH, VeeduRN and Diermeier.SD (2021). Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci, 22:3295.
KheddoP, CliffMJ, UddinS, van der WalleCF and GolovanovAP. (2016). Characterizing monoclonal antibody formulations in arginine glutamate solutions using 1H NMR spectroscopy. MAbs, 8:1245–1258.
7.
CapaldiD, TeasdaleA, HenryS, AkhtarN, den BestenC, Gao-SheridanS, KretschmerM, SharpeN, AndresB, et al. (2017). Impurities in oligonucleotide drug substances and drug products. Nucleic Acid Ther, 27:309–322.
8.
PourshahianS. (2021). Therapeutic oligonucleotides, impurities, degradants, and their characterization by mass spectrometry. Mass Spectrom Rev, 40:75–109.
9.
MuslehiddinogluJ, SimlerR, HillML, MuellerC, AmeryJH, DixonL, WatsonA, StorchK, GazziolaC, et al. (2020). Technical considerations for use of oligonucleotide solution API. Nucleic Acid Ther, 30:189–197.
10.
PhyoP, ZhaoX, TempletonAC, XuW, CheungJK and SuY. (2021). Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Adv Drug Deliv Rev, 174:1–29.
11.
WangD, ParkJ, PatilSM, SmithCJ, LeazerJLJr., KeireDA and ChenK. (2020). An NMR-based similarity metric for higher order structure quality assessment among U.S. marketed insulin therapeutics. J Pharm Sci, 109:1519–1528.
12.
GhasrianiH, HodgsonDJ, BrinsonRG, McEwenI, BuhseLF, KozlowskiS, MarinoJP, AubinY and KeireDA. (2016). Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars. Nat Biotechnol, 34:139–141.
13.
AubinY, GingrasG and SauvéS. (2008). Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor. Anal Chem, 80:2623–2627.
14.
ArbogastLW, BrinsonRG and MarinoJP. (2015). Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance. Anal Chem, 87:3556–3561.
15.
ArbogastLW, BrinsonRG and MarinoJP. (2016). Application of natural isotopic abundance 1H-13C- and 1H-15N-correlated two-dimensional NMR for evaluation of the structure of protein therapeutics. Methods Enzymol, 566:3–34.
16.
ArbogastLW, DelaglioF, SchielJE and MarinoJP. (2017). Multivariate analysis of two-dimensional 1H, 13C methyl NMR spectra of monoclonal antibody therapeutics to facilitate assessment of higher order structure. Anal Chem, 89:11839–11845.
17.
BarnwalRP, YangF and VaraniG. (2017). Applications of NMR to structure determination of RNAs large and small. Arch Biochem Biophys, 628:42–56.
18.
FürtigB, RichterC, WöhnertJ and SchwalbeH. (2003). NMR spectroscopy of RNA. ChemBioChem, 4:936–962.
19.
WijmengaSS and Van BuurenBNM. (1998). The use of NMR methods for conformational studies of nucleic acids. Prog Nucl Magn Reson Spectrosc, 32:287–387.
20.
KovacsH, MoskauD and SpraulM. (2005). Cryogenically cooled probes—a leap in NMR technology. Prog Nucl Magn Reson Spectrosc, 46:131–155.
21.
Wishart DS. (2013). Characterization of biopharmaceuticals by NMR spectroscopy. TrAC Trends Anal Chem, 48:96–111.
22.
SchandaP and BrutscherB. (2005). Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J Am Chem Soc, 127:8014–8015.
23.
FarjonJ, BoisbouvierJ, SchandaP, PardiA, SimorreJ-P and BrutscherB. (2009). Longitudinal-relaxation-enhanced NMR experiments for the study of nucleic acids in solution. J Am Chem Soc, 131:8571–8577.
24.
SathyamoorthyB, LeeJ, KimseyI, GanserLR and Al-HashimiH. (2014). Development and application of aromatic [13C, 1H] SOFAST-HMQC NMR experiment for nucleic acids. J Biomol NMR, 60:77–83.
25.
SchandaP, KupĉeE and BrutscherB. (2005). SOFAST-HMQC experiments for recording two-dimensional deteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR, 33:199–211.
26.
RobsonS, ArthanariH, HybertsSG and WagnerG. (2019). Nonuniform sampling for NMR spectroscopy. Methods Enzymol, 614:263–291.
27.
BecetteOB, ZongG, ChenB, TaiwoKM, CaseDA and DayieTK. (2020). Solution NMR readily reveals distinct structural folds and interactions in doubly 13C- And 19F-labeled RNAs. Sci Adv, 6:1–8.
28.
HennigM, ScottLG, SperlingE, BermelW and WilliamsonJR. (2007). Synthesis of 5-fluoropyrimidine nucleotides as sensitive NMR probes of RNA structure. J Am Chem Soc, 129:14911–14921.
29.
ScottLG and HennigM. (2016). 19F-site-specific-labeled nucleotides for nucleic acid structural analysis by NMR. Methods Enzymol, 566:59–87.
BrinsonRG, MillerJT, KahnJD, Le GriceSFJ and MarinoJP. (2016). Applying thymine isostere 2,4-difluoro-5-methylbenzene as a NMR assignment tool and probe of homopyrimidine/homopurine tract structural dynamics. Methods Enzymol, 566:89–110.
32.
GrzesiekS and BaxA. (1993). The importance of not saturating water in protein NMR. Application to sensitivity enhancement and NOE measurements. J Am Chem Soc, 115:12593–12594.
33.
PiottoM, SaudekV and SklenářV. (1992). Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR, 2:661–665.
34.
Hoult DI. (1976). Solvent peak saturation with single phase and quadrature fourier transformation. J Magn Reson, 21:337–347.
35.
KupceE and FreemanR. (1994). Wideband excitation with polychromatic pulses. J Magn Reson Ser A, 108:268–273.
WishartDS, BigamCG, YaoJ, AbildgaardF, DysonHJ, OldfieldE, MarkleyJL and SykesBD. (1995). 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J Biomol NMR, 6:135–140.
38.
KhatunR, HunterHN, ShengY, CarpickBW and KirkitadzeMD. (2018). 27Al and 31P NMR spectroscopy method development to quantify aluminum phosphate in adjuvanted vaccine formulations. J Pharm Biomed Anal, 159:166–172.
39.
RosenauCP, JelierBJ, GossertAD and TogniA. (2018). Exposing the origins of irreproducibility in fluorine NMR spectroscopy. Angew Chemie Int Ed, 57:9528–9533.
40.
DelaglioF, GrzesiekS, VuisterGW, ZhuG, PfeiferJ and BaxA. (1995). NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR, 6:277–293.
41.
JohnsonBA and BlevinsRA. (1994). NMR View: a computer program for the visualization and analysis of NMR data. J Biomol NMR, 4:603–614.
42.
SternAS, DonohoDL and HochJC. (2007). NMR data processing using iterative thresholding and minimum l1-norm reconstruction. J Magn Reson, 188:295–300.
43.
ShahS and FriedmanSH. (2008). An ESI-MS method for characterization of native and modified oligonucleotides used for RNA interference and other biological applications. Nat Protoc, 3:351–356.
44.
ZhaoC, DevanyM and GreenbaumNL. (2014). Measurement of chemical exchange between RNA conformers by 19F NMR. Biochem Biophys Res Commun, 453:692–695.
45.
EratMC, BesicE, OberhuberM, JohannsenS and SigelRKO. (2018). Specific phosphorothioate substitution within domain 6 of a group II intron ribozyme leads to changes in local structure and metal ion binding. J Biol Inorg Chem, 23:167–177.
46.
IwamotoN, ButlerDCD, SvrzikapaN, MohapatraS, ZlatevI, SahDWY, Meena, StandleySM, LuG, et al. (2017). Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol, 35:845–851.
47.
LiuY, DodartJ-C, TranH, BerkovitchS, BraunM, ByrneM, DurbinAF, HuXS, IwamotoN, et al. (2021). Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun, 12:847.
48.
PodbevsekP, AllersonCR, BhatB and PlavecJ. (2010). Solution-state structure of a fully alternately 2′-F/2′-OMe modified 42-nt dimeric siRNA construct. Nucleic Acids Res, 38:7298–7307.
49.
Župerl Š, PristovšekP, MenartV, Gaberc-PorekarV and NovičM. (2007). Chemometric approach in quantification of structural identity/similarity of proteins in biopharmaceuticals. J Chem Inf Model, 47:737–743.
50.
JapeljB, IlcG, MarušičJ, SenčarJ, KuzmanD and PlavecJ. (2016). Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies. Sci Rep, 6:1–12.
51.
BrinsonRG and MarinoJP. (2019). 2D J-correlated proton NMR experiments for structural fingerprinting of biotherapeutics. J Magn Reson, 307:106581.
52.
LuyB and MarinoJP. (2001). 1H-31P CPMG-correlated experiments for the assignment of nucleic acids. J Am Chem Soc, 123:11306–11307.
53.
ElliottKW, GhasrianiH, WikströmM, GiddensJP, AubinY, DelaglioF, MarinoJP and ArbogastLW. (2020). Comparative analysis of one-dimensional protein fingerprint by line shape enhancement and two-dimensional 1H,13C methyl NMR methods for characterization of the higher order structure of IgG1 monoclonal antibodies. Anal Chem, 92:6366–6373.
54.
BrinsonRG, ArbogastLW, MarinoJP and DelaglioF. (2020). Best practices in utilization of 2D-NMR spectral data as the input for chemometric analysis in biopharmaceutical applications. J Chem Inf Model, 60:2339–2355.
55.
United States Food and AdministrationDrug. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. United States Food and Drug Administration, Silver Spring,MD.
56.
United States Food and AdministrationDrug. (2016). Clinical pharmacology data to support demonstration of biosimilarity: guidance for industry. United States Food and Drug Administration, Silver Spring,MD.
57.
United States Food and AdministrationDrug. (2019). Considerations in demonstrating interchangeability with a reference product: guidance for industry. United States Food and Drug Administration, Silver Spring,MD.
58.
European Medicines Agency. (2005). ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products. European Medicines Agency, London,UK.
59.
BrinsonRG, MarinoJP, DelaglioF, ArbogastLW, EvansRM, KearsleyA, GingrasG, GhasrianiH, AubinY, et al. (2019). Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs, 11:94–105.
60.
PoppeL, JordanJB, LawsonK, JerumsM, ApostolI and SchnierPD. (2013). Profiling formulated monoclonal antibodies by 1H NMR spectroscopy. Anal Chem, 85:9623–9629.
61.
FranksJ, GlushkaJN, JonesMT, LiveDH, ZouQ and PrestegardJH. (2016). Spin diffusion editing for structural fingerprints of therapeutic antibodies. Anal Chem, 88:1320–1327.
62.
SheenDA, ShenVK, BrinsonRG, ArbogastLW, MarinoJP and Delaglio.F (2020). Chemometric outlier classification of 2D-NMR spectra to enable higher order structure characterization of protein therapeutics. Chemom Intell Lab Syst, 199:103973.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
